Amundi Asset Management US Inc. lifted its stake in shares of HCA Healthcare, Inc. (NYSE:HCA) by 101.4% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 774,020 shares of the company’s stock after buying an additional 389,617 shares during the quarter. Amundi Asset Management US Inc.’s holdings in HCA Healthcare were worth $145,779,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Verition Fund Management LLC bought a new position in HCA Healthcare in the 1st quarter valued at about $210,000. Morgan Stanley lifted its position in shares of HCA Healthcare by 12.6% in the 1st quarter. Morgan Stanley now owns 477,957 shares of the company’s stock worth $90,019,000 after purchasing an additional 53,610 shares during the period. Alyeska Investment Group L.P. increased its stake in shares of HCA Healthcare by 4.3% in the 1st quarter. Alyeska Investment Group L.P. now owns 266,089 shares of the company’s stock valued at $50,115,000 after acquiring an additional 11,080 shares in the last quarter. Cubist Systematic Strategies LLC increased its stake in HCA Healthcare by 5.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 28,275 shares of the company’s stock valued at $5,325,000 after purchasing an additional 1,570 shares in the last quarter. Finally, Glenmede Trust Co. NA bought a new stake in shares of HCA Healthcare in the 1st quarter worth $272,000. 68.68% of the stock is currently owned by institutional investors and hedge funds.
In other news, insider A Bruce Moore, Jr. sold 12,000 shares of the stock in a transaction dated Monday, May 3rd. The shares were sold at an average price of $205.32, for a total transaction of $2,463,840.00. Following the transaction, the insider now owns 102,381 shares of the company’s stock, valued at $21,020,866.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Jonathan B. Perlin sold 37,305 shares of the firm’s stock in a transaction dated Friday, April 23rd. The stock was sold at an average price of $200.03, for a total transaction of $7,462,119.15. The disclosure for this sale can be found here. Over the last quarter, insiders sold 342,446 shares of company stock valued at $68,773,585. 1.60% of the stock is owned by insiders.
HCA Healthcare (NYSE:HCA) last released its earnings results on Monday, July 19th. The company reported $4.37 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.16 by $1.21. The company had revenue of $14.44 billion for the quarter, compared to analysts’ expectations of $13.61 billion. HCA Healthcare had a return on equity of 234.29% and a net margin of 8.87%. The firm’s quarterly revenue was up 30.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.23 EPS. Equities analysts anticipate that HCA Healthcare, Inc. will post 16.7 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 30th. Investors of record on Thursday, September 16th will be given a $0.48 dividend. This represents a $1.92 annualized dividend and a dividend yield of 0.77%. The ex-dividend date of this dividend is Wednesday, September 15th. HCA Healthcare’s dividend payout ratio (DPR) is currently 16.54%.
Several equities research analysts have commented on HCA shares. Zacks Investment Research downgraded shares of HCA Healthcare from a “buy” rating to a “hold” rating and set a $218.00 price objective on the stock. in a report on Tuesday, June 15th. Citigroup upped their price objective on shares of HCA Healthcare from $215.00 to $268.00 and gave the stock a “neutral” rating in a research report on Wednesday. Mizuho increased their price target on shares of HCA Healthcare from $232.00 to $275.00 and gave the company a “buy” rating in a research report on Wednesday. Jefferies Financial Group reissued a “buy” rating on shares of HCA Healthcare in a research note on Friday, June 18th. Finally, Oppenheimer raised their price objective on HCA Healthcare from $230.00 to $275.00 and gave the company an “outperform” rating in a research report on Wednesday. Four equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $233.86.
About HCA Healthcare
HCA Healthcare, Inc, through its subsidiaries, operates as a health care services company in the United States. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.
Recommended Story: Mutual Funds
Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare, Inc. (NYSE:HCA).
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.